Chembio diagnostics, Inc.
CEMI
CEMI was delisted on the 27th of April, 2023.
1 hedge funds and large institutions have $170 invested in Chembio diagnostics, Inc. in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 29 closing their positions.
97% less funds holding
Funds holding: 30 → 1 (-29)
100% less capital invested
Capital invested by funds: $1.36M → $170 (-$1.36M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 29
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$690K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$124K |
| 3 |
BlackRock
New York
|
-$91.1K |
| 4 |
PCM
PenderFund Capital Management
Vancouver,
British Columbia, Canada
|
-$88K |
| 5 |
Renaissance Technologies
New York
|
-$69K |
CEMI Hedge Fund Activity: Q2 2023 in Review
1 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Chembio diagnostics, Inc. (CEMI) for Q2 2023, worth a combined $170 — down 100% from $1.36M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of CEMI and 0 opened new positions — a net loss of 29 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $690K sold.
- 1 institutional investor held Chembio diagnostics, Inc. (CEMI) as of Q2 2023, down from 30 in Q1 2023.
- Funds reported $170 of Chembio diagnostics, Inc. stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new Chembio diagnostics, Inc. positions in Q2 2023 and 29 closed out, a net change of -29 holders.
- The largest Chembio diagnostics, Inc. seller in Q2 2023 was Vanguard Group, an estimated $690K sold.
Based on aggregated 13F filings for Q2 2023.